Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

“卵巢癌几乎被认为对现有的免疫疗法没有反应，所以对我们来说，通过阻断这种分子，IL-4，改变肿瘤的微环境，我们可以使这些难以治疗的肿瘤更容易治疗，这让我们感到非常震惊。”“这进一步证明，针对肿瘤附近，而不仅仅是癌细胞，可能是有益的。” ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

(NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as 1 year of age.

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. Tue, Nov 5, 2024, 10:00 PM 16 ...